Threat of Heart Diseases and Physic on Account of Blood Sugar (Glucose) and The Fluid Rest of the Blood Clotting Concentration of an Endogenous methylated amino acid (EMAA) Derived from Arginine
Keywords:EMAA, Arginine, Clotting etc.
Endogenous methylated amino acid (EMAA) is a nonselective nitric oxide (NO) syntheses’ inhibitor associated with heart diseases and metabolic disorders. EMMA plays an important role in the regulation of vascular tone by acting as an endogenous inhibitor of NO synthesis. This study aimed to investigate EMMA with respect to diabetes and its clinical relevance as an independent predictor of heart diseases and physic. The current folder manage learning includes twenty blood sugar (glucose) suffering people chosen indiscriminately. The fluid rest of the blood clotting concentration of an endogenous methylated amino acid (EMAA) derived from Arginine analyzed by using enzyme immunoassay for the quantitative determination of endogenous EMAA, and blood serum nitric oxide was determined.
R. Candido, P. Srivastava, M. E. Cooper, and L. M. Burrell, “Diabetes mellitus: a cardiovascular disease,” Current Opinion in Investigational Drugs, vol. 4, no. 9, pp. 1088–1094, 2003.
C. Nielson and T. Lange, “Blood glucose and heart failure in nondiabetic patients,” Diabetes Care, vol. 28, no. 3, pp. 607–611, 2005.
B. Tesfamariam, M. L. Brown, and R. A. Cohen, “15-Hydro- xyeicosatetraenoic acid and diabetic endothelial dysfunction in rabbit aorta,” Journal of Cardiovascular Pharmacology, vol. 25, no. 5, pp. 748–755, 1995.
J. P. Cooke and V. J. Dzau, “Nitric oxide synthase: role in the genesis of vascular disease,” Annual Review of Medicine, vol. 48, pp. 489–509, 1997.
J. P. Cooke, “Does ADMA cause endothelial dysfunction?” Arte- riosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 9, pp. 2032–2037, 2000.
J. T. Kielstein, R. H. Bo¨ger, S. M. Bode-Bo¨ger et al., “Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease,” Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 594–600, 1999.
C. Zoccali, S. M. Bode-Bo¨ger, F. Mallamaci et al., “Plasma con- centration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study,” Lancet, vol. 358, no. 9299, pp. 2113–2117, 2001.
D. V. Kumar, P. Y. K. . Dwivedi, P. R. Bansal, and D. P. . Agrawal, “Mathematical Models on Acute Lymphoblastic Leukemia(ALL)”, IJMREAD, pp. 18–21, May 2022.
D. Sharma and D. P. Kumar, “ Role of Cyclin Dependent Kinase Inhibitors as Anticancer Drug in Present Medicinal System”, IJMREAD, pp. 01–07, Apr. 2021.
How to Cite
Copyright (c) 2022 Dr. Pramod Kumar, Dr. Hemant Baghel, Dr. Shiv Jee Malveeya, Shiv Kumar Upadhyay
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.